Julie Avolio
Overview
Explore the profile of Julie Avolio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Terrance M, Gunawardena T, Ouyang H, Avolio J, Duan W, Thanikachalam S, et al.
Methods Mol Biol
. 2023 Oct;
2725:213-223.
PMID: 37856027
Primary human nasal epithelial cell (HNEC) cultures serve as an excellent model in studying physiology, disease, and therapy related to the respiratory tract. The current chapter details protocols from sample...
2.
Mouzaki M, Dupuis A, Avolio J, Griffin K, Ratjen F, Tullis E, et al.
Front Pharmacol
. 2023 Jul;
14:1157459.
PMID: 37521467
Ivacaftor, the first CFTR modulator drug, leads to significant long-term improvement in lung function and weight gain. The mechanism as well as the long-term impact of ivacaftor on weight, resting...
3.
Birimberg-Schwartz L, Ip W, Bartlett C, Avolio J, Vonk A, Gunawardena T, et al.
Life Sci Alliance
. 2023 Apr;
6(6).
PMID: 37024122
Highly effective drugs modulating the defective protein encoded by the CFTR gene have revolutionized cystic fibrosis (CF) therapy. Preclinical drug-testing on human nasal epithelial (HNE) cell cultures and 3-dimensional human...
4.
Mastromatteo S, Chen A, Gong J, Lin F, Thiruvahindrapuram B, Sung W, et al.
HGG Adv
. 2022 Nov;
4(1):100156.
PMID: 36386424
Phasing of heterozygous alleles is critical for interpretation of -effects of disease-relevant variation. We sequenced 477 individuals with cystic fibrosis (CF) using linked-read sequencing, which display an average phase block...
5.
Gong J, He G, Wang C, Bartlett C, Panjwani N, Mastromatteo S, et al.
NPJ Genom Med
. 2022 Apr;
7(1):28.
PMID: 35396391
Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) are CF-causing. CFTR modulators target variants to improve lung function, but marked variability in response exists and current...
6.
He G, Panjwani N, Avolio J, Ouyang H, Keshavjee S, Rommens J, et al.
J Cyst Fibros
. 2022 Feb;
21(4):616-622.
PMID: 35190293
Background: Variation in respiratory response to cystic fibrosis (CF) small molecule therapies is due in part to the contribution of CF lung disease modifier genes. Cultured human bronchial epithelia (HBE)...
7.
Jacobi E, Solomon M, Avolio J, Shaw M, Gonska T, Ratjen F, et al.
J Cyst Fibros
. 2022 Jan;
21(2):e102-e105.
PMID: 35063397
Aquagenic wrinkling of palms (AWP) in cystic fibrosis (CF) patients and common CFTR mutations is recognized as a frequent symptom of the disease. The long-term effect of CFTR targeting therapy...
8.
Duan W, Cen Y, Lin C, Ouyang H, Du K, Kumar A, et al.
ERJ Open Res
. 2021 Sep;
7(3).
PMID: 34527729
Respiratory syncytial virus (RSV) infections in early life predispose children with cystic fibrosis (CF) to more severe lung function decline in later life. The mechanisms explaining the associations between RSV...
9.
Lin Y, Keenan K, Gong J, Panjwani N, Avolio J, Lin F, et al.
Genet Med
. 2021 Aug;
23(11):2235-2236.
PMID: 34389817
No abstract available.
10.
Lin Y, Keenan K, Gong J, Panjwani N, Avolio J, Lin F, et al.
Genet Med
. 2021 Jan;
23(5):927-933.
PMID: 33500570
Purpose: Cystic fibrosis (CF), caused by pathogenic variants in the CF transmembrane conductance regulator (CFTR), affects multiple organs including the exocrine pancreas, which is a causal contributor to cystic fibrosis-related...